Exam 2: Platelets and Coagulation Flashcards
Platelet
Functions
- Limit bleeding after injury to a blood vessel
- Promote vessel repair
- Regular maintenance of an intact endothelium
Platelet Count
Normal range: 150,000 - 450,000 platelets/microliter
Thrombocytopenia
-
Abnormally low platelet count
- < 150,000/microliter
-
Characterized by:
- Easy bruising
- Nose bleeds
- Petechial rash
- Spontaneous bleeding
- Occurs below 20,000 platelets/microliter
Idiopathic Thrombocytopenic Purpura
(ITP)
Autoimmune disease where anti-platelet Ab destroy platelets.
Platelet
Lifecycle
- Derived from bone marrow cells called megakaryocytes
- Lifespan ~ 8-10 days
- Removed by sleen or via clotting process

Platelet
Morphology
Small, flat, disc-shaped membrane-enclosed bits of cytoplasm.
Hyalomere
- Clear outer region
- Contains bundles of microtubules
- Helps maintain discoid shape
- Contains actin & myosin
- Involved in shape change of activated platelets
Granulomere
- Central region with basophilic stippling
- Contains usual cytoplasmic organelles
- Contains at least 3 types of granules
- Alpha, Delta, and Lambda
2 systems of membrane bound channels:
-
Open canalicular system
- Invaginations of the plasma membrane
- Facilitates rapid exocytosis of granules
-
Dense tubular system
- Stores Ca2+ needed for exocytosis
- Not continuous with the plasma membrane

Alpha (α) Granules
Contains:
Platelet-derived growth factor (PDGF) ⇒ mitogen for vessel repair
von Willebrand Factor (vWF) ⇒ mediates platelet adhesion to endothelium (collagen and laminin)

Delta (δ) Granules
Contains:
Ca2+, ATP, ADP ⇒ all enhance platelet aggregation
Serotonin ⇒ vasoconstriction
(Picked up by platelets in circulation)

Lambda (λ) Granules
Contains:
Lysosomal enzymes ⇒ clot resorption

Vessel Repair
Process
Adhesion
-
vWF binds to components of the damaged basement membrane (collagen, laminin)
- vWF can be secreted by many cells including platelets
- vWF attracts platelets which have surface receptor for vWF
- Single layer of platelets forms @ site of endothelial damage
Aggregation
- Adhered platelets secrete fibrinogen
- Other platelets attracted to the site via cell surface receptors for fibrinogen
- Fibrinogen links the platelets together
-
Forms a multilayered primary hemostatic plug
- Fills the defect in the vessel wall
Activation
- Aggregation causes platelet activation
- Results in:
- Secretion of granule mediators
-
Synthesis and release of aracidonic acid derivatives
- Thromboxane A2 (TXA2)
-
Change of platelet shape
- Mediated by the hyalomere
- Released mediators cause:
-
Further platelet aggregation
- TXA2, serotonin, and Ca2+
-
Vasoconstriction (limits bleeding)
- Serotonin and TXA2
-
Blood coagulation
- Platelets release several coagulating factors from α-granules
- Meshwork of fibrin formed which stabilizes the platelet plug forming the secondary hemostatic plug
-
Further platelet aggregation
Clot Retraction
- After ~ 1 hr, platelets contract due to actin-myosin interaction
- Platelet plug ↓ in size & flattens against vessel wall
- Helps to re-establish smooth blood flow
Clot Resorption
- Mediated partially by lysosomal enzymes from λ-granules
Vessel Repair
- Mediated by platelet-derived growth factor (PDGF) from α-granules
- PDGF is strongly mitogenic for cells needed to rebuild the vessel wall including:
- Endothelial cells
- Fibroblasts
- Smooth muscle

Platelet Activation
Regulation
-
Platelets activated upon binding to collagen and laminin of damaged basement membrane
- Not exposed in healthy vessels
- Healthy endothelial cells produce factors that inhibit platelet aggregation
- Ex. Prostacyclin I2 (PGI2) from arachidonic acid

Aspirin
Inhibits cyclooxygenase activity
- ↓ platelet function
- Prolongs bleeding times

Thrombosis
Formation of a clot (thrombus)
- Can cause serious damage
- Can lead to death if vessel occluded

Thrombus
Charactertistics
- Meshwork of fibrin + plug of activated platelets
- Clotting occurs in association with membranes
- Pathology:
- In coronary arteries ⇒ MI
- In cerebral arteries ⇒ ischemic stroke
- In peripheral arteries ⇒ claudication (leg pain with exercise) or amputation
- In deep veins ⇒ DVT
Embolus
A mass traveling through the circulation.
Can be a thrombus broken off a site of coagulation.
If thrombus lodges in the lung ⇒ pulmonary embolism (PE)
Blood Clotting
Overview
Initiated on the membranes of endothelial cells and platelets:
- Formation of a fibrin clot
- Formation of a platelet plug
- Vasoconstriction (eicosanoids, PGs, Txs)
- Limits to the process (anticoagulation)
- Clot dissolution (fibrinolysis)
- Wound repair
Functions through cascade of proteolytic cleavage or conformational changes.
Fibrin Clot Formation
Charactertistics
- Intrinsic and extrinsic pathways converge on the final common pathway
-
Major factors
- Named by Roman numerals & common names
- Factor IX = Christmas factor
- Are glycoproteins synthesized primarily by the liver
- Named by Roman numerals & common names
-
Functions using cascades
- Activation primarily by proteolytic cleavage
- Successive proteins are serine proteases
- Cleaves peptide bond on carboxyl side of Arg or Lys
- Activation can also be caused by conformational changes
- Facilitates acceleration and amplification of process
- Non-proteolytic proteins also needed ⇒ accessory proteins (cofactors)

Clotting Effectors
Presence accelerates the rate of certain steps in fibrin clot formation:
-
Negatively charged phospholipids (PS, PI)
- Normally found on inner leaflet of plasma membrane
- Exposure signals injury
-
Ca2+
- Binds negatively charged γ-carboxyglutamate (Gla) residues on certain clotting proteins
- Facilitates binding of these proteins to exposed negatively charged phospholipids

Gla Proteins
Factors II, VII, IX, X
- Contains negatively charged γ-carboxyglutamate (Gla) residues
-
γ-carboxylation
-
Post-translational modification
- 9-12 Glu residues @ N-terminus carboxylated to Gla residues by glutamyl carboxylase
- Occurs in lumen of RER in hepatocytes
-
Vit K required as co-enzyme
- Oxidized in reaction to epoxide
- Must be reduced back to hydroquinone form to continue
- Done by Vitamin K epoxide reductase (VKOR)
-
Post-translational modification

Dicumarol
&
Warfarin (Coumadin)
⊗ reduction of Vit K by VKOR
- Inhibits clotting by depleting pool of Vit K
- Oral administration
- Slow onset
- Long half-life
- Polymorphisms in cytochrom P450 and VKOR isozymes results in varied dosing

Tissue Factor
(TF)
-
Transmembrane glycoprotein
- Abundant in vascular subendothelium
- Released by damaged tissue ⇒ extravascular
-
Key protein in the extrinsic pathway
- Pathway is quickly shut down by tissue factor pathways inhibitors (TFPI)

Extrinsic Pathway
“Tissue Factor Pathway”
- Vascular injury exposes extravascular TF (Factor III) to Factor VII
- TF binding causes conformation change of VII activating it to VIIa
- VII can also be activated by Factor XIIa from intrinsic path or thrombin (IIa) from common path
- VIIa is a serine protease which activates factor X
- Factor Xa enters the common pathway
Extrinsic pathway is quickly shut down by tissue factor pathway inhibitors (TFPI).

Intrinsic Pathway
“Contact Pathway”
All protein factors are found in the blood ⇒ intravascular
Contact Phase
Results in the activation of factor XII → XIIa
-
Contact of blood with a negatively charged surface ⇒ conformational change & activation of factor XII → XIIa
- In vitro ⇒ glass blood vials
- Sodium citrate/oxalate added to chelate Ca2+ and prevent clotting
- In vivo ⇒ ⊖ PL on damaged endothelium or an abnormal surface
- E.g. mechanical heart valve, stent, knee/hip replacements
- In vitro ⇒ glass blood vials
-
Amplification of contact phase
-
Factor XIIa cleaves Prekallikrein-HMWK at an anionic surface producing Kallikrein
- HMWK = High molecular weight kininogen
- Kallikrein can then proteolytically cleave additional Factor XII ⇒ amplification
-
Factor XIIa cleaves Prekallikrein-HMWK at an anionic surface producing Kallikrein
No known bleeding disorders associated with factor deficiencies of the contact phase.
X Activation Phase
-
Factor XIIa cleaves XI-HMWK at an anionic surface to produce Factor XIa
- Factor XI can also be activated by Thrombin from common pathway
- Defective Factor XI → Hemophilia C
-
Factor XIa cleaves Factor IX (Christmas factor) → IXa
- Defective Factor IX → Hemophilia B
- Can also be cleaved by Factor VIIa from extrinsic pathway
-
Factor IXa combines with Factor VIIIa
- Interaction with VIIIa ↑↑↑ rxn rate
- Factor VIII found in the blood bound to von Willebrand factor (vWF)
- vWF protects VIII from degradation
- Thrombin from common pathway cleaves vWF off VIII activating it
- Defective Factor VIII → Hemophilia A
-
IXa:VIIIa complex cleaves Factor X → Xa
- Factors VIIIa, IXa, 10, and Ca2+ on membrane ⇒ Tenase complex

Hemophilia
-
Coagulopathy caused by clotting factor deficiencies
- Factor VIII ⇒ Hemophilia A
- 6x more common than B
- Found on chromosome Xq
- Factor IX ⇒ Hemophilia B
- Found on chromosome Xq
- Factor XI ⇒ Hemophilia C
- Autosomal recessive
- Factor VIII ⇒ Hemophilia A
- Manifestations
- Decreased/delayed ability to clot
- Formation of abnormally friable clots
- Severity related to residual activity
- Effects seen if < 30% activity
- Severe form if < 1% activity
- Spontaneous, prolonged bleeding particularly into joints and muscle
- Treatment
- Recombinant factor replacement
- Somatic gene therapy in development
Common Pathway
Factor Xa to Fibrin:
-
Factor Xa from both intrinsic and extrinsic paths associates with Factor Va(accessory protein) forming Xa-Va ⇒ Prothrombinase complex
- Binding of Va ⇒ 20x ↑ in Xa activity
- Binding of Ca2+ to Gla residue on Prothrombin (Factor II) facilitates binding of Prothrombin to membrane and to Xa-Va complex
- Xa-Va complex cleaves Prothrombin (II) → Thrombin (IIa)
- Excises Gla region releasing Thrombin from the membrane
- Only time Gla excised
- Gla-peptide remains bound to membrane surface
- Taken up by the liver
- Excises Gla region releasing Thrombin from the membrane
- Thrombinplasma cleaves Fibrinogen (Factor I) → Fibrin (Ia)
- Fibrin forms the fibrin soft clot
- Thrombinplasma activates Factor XIII → XIIIa
-
Factor XIIIa (transglutaminase) cross-links Gln from one fibrin with Lys of another ⇒ isopeptide bond
- Converts soft clot into an insoluble hard clot

Fibrin
-
Fibrinogen
- Soluble glycoprotein made by the liver
- Dimers of three different polypeptides held together at N-termini by disulfide bonds
- N-termini of the chains form “tufts” on the central three globular domains (D, E, D)
-
Thrombin cleaves the negatively charged tufts producing fibrinopeptides:
- Fibrinogen → fibrin monomers
- Solubility decreases
- Fibrin monomers associate laterally
- Soft fibrin clot formed

Roles of Thrombin

Blood Clotting
Complete Pathway
Pathway Interconnections:
- Factor VIIa of extrinsic path activates factor IX of intrinsic path
- Factor XIIa of intrinsic path activates factor VII of extrinsic path
-
Thrombin (IIa) of common path activates factors of intrinsic and extrinsic paths
- Factors 7, 12, 11, 8, and 5

Clotting Factors
Classifications

Platelet plug provides…
primary hemostasis
Fibrin net provides…
secondary hemostasis
Platelet Plug
Formation
- vWF binds exposed collagen on endothelial surface
-
Platelets bind:
-
To vWF via GP1b
- Part of the membrane receptor complex (GP1b/V/IX)
- vWF made by endothelial cells and megakaryocytes
- Part of the membrane receptor complex (GP1b/V/IX)
- Directly to collagen via GPVI
-
To vWF via GP1b
- Binding stops forward movement of platelets causing adherence
- Platelet activation causes degranulation
- Thrombin is the most potent activator
- Required for platelet activation and fibrin formation
- Also exposes anionic PL which allows formation of tenase complex on surface of platelets
- Thrombin is the most potent activator
- Conformational Δ following activation leads to platelet aggregation
- Forms the platelet plug ⇒ primary hemostasis
- Conformational Δ in GPIIb/IIIa receptor exposes fibrinogen binding sites
- Fibrinogen binds & links activated platelets to one another
- Fibrinogen → Fibrin by Thrombin (IIa)
- Cross linkage by Factor XIIIa from plasma and platelets
-
Fibrin net strengthens platelet plug to resist shear forces
- Achieves secondary hemostasis
Platelet Activation
-
Thrombin binds to and activates protease-activated receptors (PARs) on the surface of platelets & endothelial cells
- Type of Gq receptor
- Receptor activates PLC which cleaves PIP2 → DAG and IP3
- DAG activates PKC leading to degranulation
- IP3 causes release of Ca2+ from delta granules
-
Calcium causes:
-
Shape changes in platelet
- Ca2+ activates MLCK which phosphorylates MLC
- Favors association with actin
-
Activation of PLA2
- Synthesis of TXA2
- Platelet degranulation
- Vasoconstriction
- Via serotonin
- Activation of additional platelets
- By binding to GPCR on platelet membrane
- Synthesis of TXA2
-
Shape changes in platelet

Platelet Activation
Regulation
- Vascular wall is separated from blood by endothelial cells
- Components like collagen and laminin are not exposed
- Endothelial cells synthesize the vasodilators PGI2 and NO
- Endothelial cells have a cell surface ADPase that converts ADP → AMP
Platelet Degranulation
Degranulation releases:
- Delta granules
- Serotonin: causes vasocontriction
-
ADP: activates additional platelets
- Plavix blocks ADP receptors preventing ability to activate platelets
- Alpha granules:
- PDGF: helps in wound healing
- Factor Va
- vWF
- Fibrinogen
- Many more
Von Willebrand’s
Disease
- Deficiency of von Willebrand’s factor
- Results in abnormal platelet adhesion
- Most common inherited coagulopathy
- AR

Bernard-Soulier
Syndrome
-
Deficiency of platelet receptor for von Willebrand’s factor
- GP1b receptor
- Results in abnormal platelet adhesion

Glanzmann’s Thrombasthenia
-
Deficiency of platelet receptor for fibrinogen
- GPIIb/IIIa complex
- Results in decreased platelet aggregation

Immune thrombocytopenia
Autoimmune disorder caused by autoantibodies to platelet receptor for fibrinogen.
Pathways of Coagulation
Interrelationships
- TF—VIIa of extrinsic path activates IX of intrinsic path
- XIIa of intrinsic path activates VII of extrinsic path
- Thrombin (IIa) of common path activates components of both the intrinsic and extrinsic paths and also activates platelets
- Tenase complex of intrinsic path forms on the surface of activated platelets and damaged endothelium
- One fifth of total Va is released by activated platelets
- XIIIa and vWF present in both plasma and platelets
Antithrombin III
(AT-III)
- Made by the liver
- Serine protease inhibitor (serpin)
-
ATIII binds to and inactivates:
-
Thrombin (most important)
- Binding makes catalytic domain of thrombin inaccessible
-
Factor IXa through XIIa
- Inactivation of X is key
- Factor VIIa-TF complex
-
Thrombin (most important)
- Complexes removed by liver
- AT-III : Thrombin binding is greatly increased by heparin
- Sulfated GAG released by mast cells in response to injury

Heparin
- Therapeutically used to ↓ clot formation
- IV administration
- Rapid-onset
- Short half-life
Activated Protein C Complex
(APC)
Protein C-Protein S complex inactivates Va and VIIIa by proteolysis.
-
Protein C(Gla) activated by thrombin-thrombomodulin complex
-
Thrombomodulin expressed on the surface of undamaged endothelial cells
- Binds thrombin
- ↓ thrombin’s affinity for fibrinogen
- ↑ thrombin’s affinity for Protein C
-
Thrombomodulin expressed on the surface of undamaged endothelial cells
- Protein C complexes with Protein S(Gla) ⇒ activated Protein C complex (APC)
-
APC cleaves Va and VIIIa
- Protein S helps achor Protein C to the clot
Tissue Factor Pathway Inhibitor
(TFPI)
Protein that inhibits the extrinsic pathway shortly after its activation.
Intrinsic path becomes dominant.
Fibrinolysis
- Plasminogen binds to fibrin & incorporated into clots during formation
- Physiological activators of plasminogen bind and cleave plasminogen → plasmin
-
Tissue plasminogen activator (t-PA or TPA)
- Made by endothelial cells
- Secreted in inactive form in response to thrombin
- Becomes active when bound to fibrin-plasminogen
-
Urokinase (u-PA)
- Made in the kidney
-
Tissue plasminogen activator (t-PA or TPA)
-
Plasmin hydrolyzes fibrin clot
- Bound plasmin and TPA protected from inhibitors
- When fibrin clot is dissolved, they are exposed and inactivated
- α-2 antiplasmin ⇒ ⊗ plasmin
- PAI (plasminogen activator inhibitor) ⇒ ⊗ TPA

Plasmin
- Serine protease which degrades fibrin
- Plasminogen made by the liver & released into the blood
- Binds to fibrin and is incorportated into clots as they are formed
- Activated by TPA or u-PA
Therapeutic Fibrinolysis
Treat patients with TPA or u-PA
Thrombophilia
“Hypercoagulability”
Caused by:
- Factor V Leiden
-
G20210A prothrombin gene mutation
- ↑ factor II activity
- Most prevalent genetic risk factor for venous thrombosis in Spanish populations
- Deficiencies of proteins C, S, and ATIII
- Excess lipoprotein A
- Hyperhomocysteinemia
- Anti-phospholipid Ab ⇒ referred to as Lupus anticoagulant
Factor V Leiden
- Mutant form of factor V ⇒ resistant to APC cleavage
- Most commonly inherited thrombophilic condition
- Esp. Caucasians, specifically Scandinavians
- Heterozygotes have a 7x increased risk of forming clots
- Homozygotes have 80x increased risk
Virchow’s Triad
Three broad categories thought to contribute to thrombophilia:

Coagulation
Summary
- Tissue injury ⇒ blood vessel damage ⇒ collagen exposure
- Platelets bind collagen
- Mediated by vWF
- Platelet activation
- Thrombin is key
- Platelet degranulation and synthesis of arachidonic acid products
- Vasoconstriction
- Platelet recruitment
- Support the clotting cascade
- Factors of intrinsic, extrinsic, and common paths of clotting cascade + Ca2+ + anionic surface ⇒ fibrin clot formation
- Initial platelet plug ⇒ primary hemostasis
- Fibrin mesh ⇒ secondary hemostasis
- Clotting limited to injured site
- Proteins that inactivate thrombin ⇒ AT-III, heparin
- Proteins that degrade V & VIII ⇒ APC
- After wound is healed, fibrin clot degraded by plasmin
- Plasmin inactivated by α-2 antiplasmin
- TPA inactivated by PAI
Abnormal Clotting
Summary
Disorders of vessels, platelets, and coagulation proteins ⇒ deviations in ability to clot.
- Vessels
- Scurvy
- Plaque formation
- Hyper-Hcy
- ↑ Lp(a)
- Platelets
- ↓ number ⇒ thrombocytopenia
- ↓ function
- Deficiency of vWF ⇒ VW disease
- Deficiency of GP1b ⇒ Bernard-Soulier syndrome
- Deficiency of CPIIb/IIIa ⇒ Glanzmann thrombasthenia
- Coagulation proteins
- VIII ⇒ Hemophilia A
- IX ⇒ Hemophilia B
- XI ⇒ Hemophilia C
- Factor V Leiden
Clotting
Clinical Tests
-
Platelets
- Platelet counts
- Platelet function tests
-
Extrinsic through common path
-
Prothrombin time (PT)
- Uses thromboplastin
- Combination of PL + TF
- Expressed as INR (international normalized ratio)
- Uses thromboplastin
-
Prothrombin time (PT)
-
Intrinsic through common path
-
Activated partial thromoplastin time (aPTT)
- Uses partial thromboplastin
- Just the PL portion b/c TF isn’t needed to activate intrinsic path
- Uses partial thromboplastin
-
Activated partial thromoplastin time (aPTT)